Literature DB >> 34181132

Colorectal cancer in Crohn's disease: a series of 6 cases.

Kazuhide Ishimaru1, Tetsuro Tominaga2, Takashi Nonaka1, Akiko Fukuda1, Masaaki Moriyama1, Shosaburo Oyama1, Mitsutoshi Ishii1, Terumitu Sawai3, Takeshi Nagayasu1.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is the most malignant complication in patients with Crohn's disease (CD). We report 6 cases of CD-related CRC treated surgically at our hospital. CASE
PRESENTATION: From 2010 to 2016, six CD patients were diagnosed with CRC. All patients were diagnosed with CD at < 25 years old, and the interval from onset of CD to diagnosis of CRC was > 10 years (range, 15-42 years) in all patients. The histological type of cancer was mucinous carcinoma in two cases, well-differentiated tubular adenocarcinoma in two cases, and moderately differentiated tubular adenocarcinoma in two cases. CRC was detected by screening colonoscopy in three cases (50%), and from clinical symptoms in the remaining three cases (50%). Two cases underwent colonoscopy within 2 months after symptom onset, detecting CRC in the relatively early stage. However, one case was diagnosed with advanced-stage CRC by endoscopy 1 year after symptom onset, and experienced poor prognosis.
CONCLUSIONS: Regular surveillance colonoscopy is needed to detect early-stage CRC in CD patients. Clear surveillance methods need to be established based on evidence.

Entities:  

Keywords:  Colorectal cancer; Crohn’s disease; Surveillance

Year:  2021        PMID: 34181132     DOI: 10.1186/s40792-021-01237-0

Source DB:  PubMed          Journal:  Surg Case Rep        ISSN: 2198-7793


  2 in total

1.  Intestinal cancer in Crohn's disease.

Authors:  Hiroki Ikeuchi; Hiroki Nakano; Motoi Uchino; Mitsuhiro Nakamura; Hiroki Matsuoka; Yoshihiro Fukuda; Takayuki Matsumoto; Yoshio Takesue; Naohiro Tomita
Journal:  Hepatogastroenterology       Date:  2008 Nov-Dec

Review 2.  Malignancy in Crohn's disease.

Authors:  D Bernstein; A Rogers
Journal:  Am J Gastroenterol       Date:  1996-03       Impact factor: 10.864

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.